Regulatory issues in human gene therapy

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Protection of human subjects is the ethical and legal responsibility of investigators conducting clinical trials. Public concerns regarding recombinant DNA technology led to additional levels of oversight which are unique to human gene therapy trials. The deaths of a normal volunteer and a gene therapy subject in the late 1990s led to an intensification of oversight with new initiatives that impact gene therapy as well as other clinical investigators. This paper will review the current oversight agencies and identify areas of evolving regulations that pose particular challenges to gene therapy investigators.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalBlood Cells, Molecules, and Diseases
Issue number1
StatePublished - Jan 1 2003

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Regulatory issues in human gene therapy'. Together they form a unique fingerprint.

Cite this